Oncolytic viruses are being actively explored as cancer therapies because they preferentially infect tumor cells and cause their lysis. At the same time, the viruses can accommodate transgenes that can stimulate anti-cancer responses in the local tumor microenvironment.
Researchers from the University of Tennessee and collaborating institutions have investigated in preclinical models the use of an oncolytic herpes simplex virus (oHSV) armed with the immune-stimulating cytokine interleukin-12 (IL-12) as a potential treatment for glioblastoma. They published their results in Molecular Therapy: Oncology.
Malignant gliomas, which include glioblastomas, are the most frequent primary brain cancer and are associated with extremely poor prognosis. They nearly always recur after treatment, rapidly leading to death.
Immvira Group Co.’s oncolytic herpes simplex virus product, MVR-T3011, showed early efficacy via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer.
Immvira Group Co.’s oncolytic herpes simplex virus product, MVR-T3011, showed early efficacy via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer.
Immvira Group Co. presented positive phase I data for MVR-T3011 as an intratumoral administration (MVR-T3011 IT) at the 2021 American Society of Clinical Oncology annual meeting this month, drawing attention to oncolytic viruses developed by Chinese scientists.
